A PYMNTS Company

US: Pfizer said to weigh sale of pump unit acquired in Hospira deal

By  |  January 14, 2016

Pfizer is weighing a sale of the pumps and devices business it acquired in last year’s purchase of Hospira Inc., people with knowledge of the matter said.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The US drug maker could fetch about $2 billion from a potential sale, the people said, asking not to be identified as the details are private. The process is at a very early stage and the details could change, the people said. Pfizer may also choose not to sell the Hospira unit at this time, they said.

    New York-based Pfizer bought Hospira, which makes generic injectable drugs and devices to deliver them, for about $17 billion in a deal that closed in September. The deal bolstered Pfizer’s portfolio of established drugs, including off-patent medicines with slow growth and strong cash flow.

    Analysts have speculated that after Hospira’s assets were integrated into the company, Pfizer might split off its entire established drugs unit from the faster-growing “innovative” business that holds many of the company’s newer brand-name drugs. Selling the Hospira devices business would leave a more pure-play drugs unit for a possible spinoff.

    Full content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.